Gaudium IVF IPO Details
The key details of Gaudium IVF & Women Health’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹165 Crores |
| Price Range | ₹75 - ₹79 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 189 |
| Investment (cut-off price) | ₹14,931 |
| Pre IPO Promotor Holding | 99.99% |
| Post IPO Promotor Holding | 71.30% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Gaudium IVF IPO Timelines
The IPO process for Gaudium IVF & Women Health includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
20/02/2026
Start Date24/02/2026
End Date25/02/2026
Refund Initiation26/02/2026
Credit of Shares to Demat Ac27/02/2026
Listing DateGaudium IVF IPO Lot Size
The Gaudium IVF & Women Health IPO has a fixed lot size of 189 shares, at an upper price band of ₹79 per share. For retail investors, the minimum application is 189 shares (1 lot) amounting to ₹14,931, while the maximum application is 2,457 shares (13 lots) totaling ₹1,94,103. For Small HNI (S-HNI) investors, the minimum application is 2,646 shares (14 lots) worth ₹2,09,034, and the maximum application is 12,474 shares (66 lots) amounting to ₹9,85,446. Big HNI (B-HNI) investors are required to apply for a minimum of 12,663 shares (67 lots), totaling ₹10,00,377.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 189 | ₹14,931 |
| Retail Maximum | 13 | 2457 | ₹1,94,103 |
| S-HNI Minimum | 14 | 2646 | ₹2,09,034 |
| S-HNI Maximum | 66 | 12474 | ₹9,85,446 |
| B-HNI Minimum | 67 | 12663 | ₹10,00,377 |
Gaudium IVF IPO Subscription Status
The subscription status for Gaudium IVF & Women Health IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Gaudium IVF IPO Company Financials
Gaudium IVF & Women Health reports robust performance in FY2025 with Total Income of ₹70.96 crores, managing expenses at ₹45.54 crores, and achieving a strong PAT (Profit After Tax) of ₹19.13 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹44.26 | ₹25.95 | ₹13.53 |
| FY 2024 | ₹48.15 | ₹31.52 | ₹10.32 |
| FY 2025 | ₹70.96 | ₹45.54 | ₹19.13 |
| FY 2026 (6 M) | ₹49.75 | ₹32.97 | ₹12.51 |
About Company
Founded in March 2015, Gaudium IVF and Women Health Limited delivers assisted reproductive services across India through a hub and spoke model. The network includes more than thirty locations, comprising seven hubs and twenty eight spokes, supported by strategic alliances with infertility experts to promote awareness of Assisted Reproductive Technology and In Vitro Fertilization. Centres operate in major cities, including Delhi at Janakpuri and Kailash Colony, Mumbai at Khar West, Ludhiana, Srinagar, Patna, and Bangalore. International patients from Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman seek treatment across these facilities.
Specialized fertility services include In Vitro Fertilization, Intracytoplasmic Sperm Injection, Intrauterine Insemination, and ovulation induction, addressing diverse infertility challenges affecting both men and women. Comprehensive gynaecological care covers conditions such as PCOD, PCOS, and endometriosis, along with high risk pregnancy management for women with complex medical histories. Advanced male infertility treatments are available, including specialized sperm retrieval techniques, ensuring holistic reproductive care under expert supervision.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2015 | Healthcare | Dr Manika Khanna |
Know Before Investing
Gaudium IVF IPO Strengths
- Gaudium IVF launches as India’s first listed pure-play IVF company with established 7-hub 28-spoke network spanning metro and tier-2 cities.
- Standardized treatment protocols across spokes leverage hub expertise enabling rapid geographic penetration with controlled capex intensity.
- IVF alongside gynae consultations, diagnostics, and wellness create cross-selling opportunities and patient retention.
- Investment in wholly-owned subsidiary EKK Global launches fertility wellness products expanding revenue beyond clinical services.
- Delayed marriages, lifestyle disorders driving 15-20% annual IVF demand growth creates multi-year sector expansion opportunity.
- Metro hub positioning attracts international patients leveraging India’s cost-quality arbitrage in fertility treatments.
Gaudium IVF IPO Risks
- IVF outcomes directly impact patient acquisition and word-of-mouth referrals in reputation-driven fertility services.
- 19 new spoke centers demand local doctor recruitment, regulatory approvals, and patient awareness creation investments.
- Cloudnine, Birla Fertility, and hospital chains pressure pricing power and market share in established IVF hubs.
- ART guidelines, PCPNDT norms, and clinical establishment acts require continuous investments across multiple jurisdictions.
- Digital marketing, consultations, and counseling investments needed to convert infertility inquiries to paid cycles.
- Multiple-cycle protocols create lumpy quarterly revenues tied to patient financing availability and insurance coverage.
Swot Analysis for Gaudium IVF IPO
Strengths
Hub-and-Spoke Network, Integrated Women Healthcare, Strong Financials
Weaknesses
High Debtors Exposure, Delhi NCR Concentration, Treatment Dependency
Opportunities
Fertility Awareness Growth, Tier-2 City Penetration, FMCG Wellness Products
Threats
Competition Intensity, Economic Downturns, Regulatory Scrutiny
Company Details
Gaudium IVF & Women’s Health Ltd.
B1/51, Janak Puri, B-1, New Delhi, New Delhi, 110058
Phone: 011-4885 8585
Email: compliance@gaudiumivfcentre.com
Website: https://www.gaudiumivfcentre.com/
IPO Registar Details
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
FAQs
The key objectives of Gaudium IVF IPO are:
- Funding capital expenditure towards establishment of New IVF Centers of the Company.
- Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.
- General Corporate Purpose
Sarthi Capital Advisors Pvt. Ltd. is the book-running lead managers for the Gaudium IVF IPO.
Gaudium IVF demonstrates strong growth potential driven by rising infertility awareness and a projected 13% CAGR in the IVF market. Its hub and spoke network across 30 plus locations, expansion of new centers, proprietary treatment protocols, and international patient inflows support scalable high margin healthcare growth.
The issue price for the Gaudium IVF IPO is set between ₹75 to ₹79 per share.
To invest in one lot of Gaudium IVF IPO, you need ₹14,175 at the lower price band (₹75 per share) or ₹14,931 at the upper price band (₹79 per share) for a lot size of 189 shares.
Gaudium IVF IPO shares are scheduled to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on February 27, 2026.
Refund/unblocking of funds for Gaudium IVF IPO will begin on February 25, 2026. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Gaudium IVF IPO shares on listing day (February 27, 2026) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.